Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | ESR1 | P03372 | 1/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.68 |
| ▸ | KARS1 | Q15046 | 5/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | RXRB | P28702 | 1/20 | 0.64 |
| ▸ | RXRG | P48443 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364223 | 1.00 | CYP3A4 (0.78) | CYP3A4ALDH1A1MAPTALOX15ESR1 | |
| SCHEMBL14207873 | 0.90 | CYP3A4 (0.74) | CYP3A4ALDH1A1MAPTALOX15ESR1 | |
| 7-Oxocallitrisic Acid, Methyl Ester SCHEMBL15339316 | 0.88 | CYP3A4 (1.00) | CYP3A4ALDH1A1MAPTALOX15ESR1 | |
| SCHEMBL14201538 | 0.88 | CYP3A4 (0.74) | CYP3A4ALDH1A1MAPTALOX15ESR1 | |
| SCHEMBL15344775 | 0.86 | CYP3A4 (0.81) | CYP3A4ALDH1A1MAPTALOX15ESR1 | |
| SCHEMBL3706021 | 0.84 | CYP3A4 (0.69) | CYP3A4ALDH1A1MAPTALOX15ESR1 | |
| SCHEMBL31291111 | 0.84 | AR (0.68) | CYP3A4ALDH1A1MAPTALOX15ESR1 | |
| SCHEMBL20364222 | 0.83 | CYP3A4 (0.62) | CYP3A4ALDH1A1MAPTALOX15ESR1 | |
| SCHEMBL19283113 | 0.82 | CYP3A4 (0.74) | CYP3A4ALDH1A1MAPTALOX15ESR1 | |
| SCHEMBL15588776 | 0.81 | ESR1 (1.00) | CYP3A4ALDH1A1MAPTALOX15ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251570-A1 | ZSM-5 ZEOLITES WITH WOOD LIGNIN OXIDIZED OR NOT | Centre National de la Recherche Scientifique (FR) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022112478-A1 | ZSM-5 ZEOLITES WITH WOOD LIGNIN OXIDIZED OR NOT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-02 | — | — | WO | disclosed |
| US-20100056615-A1 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS | DSM IP ASSETS B.V. (NL) | 2010-03-04 | — | — | US | disclosed |
| US-20100056615-A1 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS | DSM IP ASSETS B.V. (NL) | 2010-03-04 | — | — | US | disclosed |
| US-7495127-B2 | Potassium channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495127-B2 | Potassium channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7385083-B2 | Potassium channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7385083-B2 | Potassium channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1925301-A1 | Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders | DSMIP Assets B.V. (NL) | 2008-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056615-A1 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS | TNF, VDR, CYP24A1 | CYP3A4 660/4885ALDH1A1 781/4885MAPT 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.